Heart Procedure Articles & Analysis
26 news found
The collaboration builds upon the ACC’s long tradition of educational excellence and will support more than 56,000 cardiovascular professionals with state-of-the-art procedural training from Osso VR to guide learning, track performance, and analyze procedures on-demand. ...
Sacramento, CA – The first MitraClip procedure using EchoPixel’s Holographic Therapy Guidance (HTG) was performed by Structural Heart Physicians at UC Davis Health. ...
Research has shown PTS quality of life scores can be as low as those of patients suffering from heart failure or cancer. Mechanical thrombectomy procedures, using technology like ClotTriever, rapidly remove large volumes of DVT and may thereby reduce the risk of ...
Most recently, he was President and CEO of Keystone Heart, a structural heart medical device company, and creator of the first Cerebral Embolic Protection device designed to provide complete coverage to all brain regions for patients undergoing cardiac procedures. Keystone Heart was acquired in 2018 by Venus Medtech, the leader ...
BySafeHeal
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP® Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. ...
The Company expects to announce these sites in the coming months. The CardiAMP Cell Therapy Heart Failure Trial is evaluating the effectiveness of the CardiAMP Cell Therapy System for improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for New York Heart Association (NYHA) Class II and III ...
“Through my work with EchoPixel, I have always envisioned someday being able to expand treatment options to patients like Sheldon, who are not traditionally felt to be good candidates for advanced heart procedures due to issues such as severe kidney disease. I believe EchoPixel’s True3D CT hologram technology, and now live 4D HTG imaging, has ...
The trial’s primary endpoint is an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. The FS procedure is a ranked analysis that compares occurrence of cardiovascular and other health-related events, along with ...
CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. The therapy incorporates a pre-procedural screening assay to identify patients who may be likely responders, a first for a cardiac cell therapy designed to enhance patient selection. Eligible ...
Average Effective Orifice Area (EOA) was up to 45% larger than those reported with other TAVR devices in matched annular sizes(2). No conduction (heart rhythm) disturbances due to the procedure. No clinically significant paravalvular regurgitation despite very complex and heavily calcified anatomy. ...
BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, and the Montreal Heart Institute (MHI), a world-renowned, ultra-specialized cardiology center, announced they are partnering to develop a new cardiovascular training solution to help cardiologists rehearse and train for complex valve-in-valve procedures. ...
ByBIOMODEX
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the first implant of theAeson artificial heart in The Netherlands. ...
ByCarmat
CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The therapy incorporates a pre-procedural screening assay to identify those patients who are likely responders to the therapy, ...
JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place in multiple centers in ...
Rather than relying on contrast dye and X-ray based imaging to help guide the implant placement, Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, performed the procedure using ultrasound-based 4D holographic imaging, which provides an image so clear that ...
About XC001 XC001 is an investigational gene therapy designed to promote the growth of new blood vessels in the heart, with these new blood vessels bypassing diseased blood vessels and improving blood flow in the heart. ...
In recognition of World Congenital Heart Defects (CHD) Awareness week, HD Medical Inc. today announces it has screened over 50,000 children for CHDs using HD Steth™. ...
The technology offers a no-implant interatrial shunt therapy for patients suffering from heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) who remain symptomatic despite optimal guideline directed medical therapy. ...
After developing the first commercially available AI software to help electrophysiologists improve management of cardiac arrythmias, Volta Medical is now preparing to transform the way ablation procedures will take place in the future. Theophile Mohr-Durdez, CEO and co-founder of Volta Medical mentioned: “We are excited to be able to complete our highly ambitious medical ...
The financing assures capital to complete clinical trials for the Ventura® Interatrial Shunt for the treatment of advanced heart failure and to obtain FDA clearance subject to final data and agency review. ...